CAMARILLO, Calif.--(BUSINESS WIRE)--Dyve Biosciences, Inc. (“Dyve”), a clinical-stage platform biotechnology company with assets in immunology and oncology, today announced that preliminary data from the ongoing pre-clinical partnership with the H. Lee Moffitt Cancer Center & Research Institute will be presented at a poster presentation at the upcoming American Association for Cancer Research (AACR) annual meeting, taking place April 14-19, 2023, in Orlando, Florida.
Dyve will present pre-clinical data from its lead oncology drug candidate, DYV800, a pH modulating agent that targets tumor microenvironment (TME) acidity in solid tumors. DYV800, delivered topically to bypass gastrointestinal absorption challenges, neutralizes the TME acidity that plays a strong role in tumor progression (invasion, metastasis, angiogenesis), immune escape, and treatment resistance (radiation, chemotherapy, and immunotherapy).
“Dyve continues to advance research in areas where we believe our pH modulation program can achieve the biggest impact for patients and we look forward to sharing new pre-clinical data on our DYV800 program at this year’s AACR. We believe we have a unique delivery approach that can unlock the powerful effects of neutralizing TME acidity, and this dataset is further validation of that,” said Ryan Beal, M.D., Chief Executive Officer, Dyve.
Poster Presentation Details:
Abstract Title: Transdermal alkalinization treatment induces pH changes in a murine melanoma model as measured with MRI-CEST pH imaging
Session Category: Tumor Biology
Session Title: Photoacoustic Ultrasound, and Fluorescence Imaging
Session Date and Time: Monday, April 17, 2023, 1:30 PM - 5:00 PM
Presenter: Dr. Pietro Irrera, H. Lee Moffitt Cancer Center & Research Institute
Location: Convention Center, Section 2, Poster Board 13
Abstract Presentation Number: 2391
About Dyve Biosciences, Inc.
Dyve Biosciences (“Dyve”) is a clinically validated biotech that is breaking barriers to deliver on the promise of pH modulation. Decades of published research demonstrate that neutralizing microenvironment acidity profoundly impacts disease, with multi-fold improvements in tumor metastases, cancer survival, and immune response. Leveraging our groundbreaking DMAX delivery platform, Dyve’s science directly targets the acidic microenvironments that drive cancer cell growth and inflammation. Dyve has demonstrated that it can deliver intuitive, targeted pH modulation to treat oncologic and immuno-inflammatory diseases. Learn more at www.dyvebio.com.